No Data
Phio Pharmaceuticals Completes Enrollment In Second Cohort In Phase 1b Dose-Escalating Clinical Study
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
Phio Pharma Shares Are Trading Higher. The Company Reported Q3 Financial Results.
Phio Pharma Q3 2024 GAAP EPS $(1.54) May Not Be Comparable To $(4.14) Estimate
Phio Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Phio Pharmaceuticals | 8-K: Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
No Data